Drug intelligence / Profile preview

anti clec2d-tlr9 agonist conjugate

Development stage: Preclinical
Lead developer: Immunitas Therapeutics

Overview

Immunitas is developing an unnamed **anti-CLEC2D–TLR9 agonist conjugate** as an oncology research program. The antibody-conjugate is designed to bind and internalize C-type lectin domain family 2 member D on myeloid cells, plasmacytoid dendritic cells, and B cells, delivering a TLR9 agonist to promote TLR-pathway activation and inflammatory cytokine production. No distinct INN, sponsor development code, or trade name has been publicly identified for this program. ([immunitastx.com](https://www.immunitastx.com/))

Targets

TLR9 (Toll-like receptor 9)CLEC2D (Lectin-like transcript 1)

Beyond the preview

Go deeper on anti clec2d-tlr9 agonist conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti clec2d-tlr9 agonist conjugate.

Explore the full profile